Cytosorbents Corp (CTSO)
NASDAQ:CTSO
Want to see CTSO full AI Analyst Report?
CTSO Stock Chart & Stats
$0.70
-$0.05(-4.55%)
At close: 4:00 PM EST
$0.70
-$0.05(-4.55%)
Day’s Range― - ―
52-Week Range$0.44 - $1.39
Previous CloseN/A
Volume86.19K
Average Volume (3M)134.35K
Market Cap
$30.83M
Enterprise Value$44.98M
Total Cash (Recent Filing)$4.81M
Total Debt (Recent Filing)$18.96M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 04, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding62,794,746
10 Day Avg. Volume163,660
30 Day Avg. Volume134,354
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)6.74
Price to Sales (P/S)1.07
P/FCF Ratio-3.17
Enterprise Value/Market Cap1.46
Enterprise Value/Revenue1.21
Enterprise Value/Gross Profit1.70
Enterprise Value/Ebitda-6.49
Forecast
1Y Price Target
$0.75Price Target Upside7.14% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$39.28M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsConsistently high gross margins reflect durable unit economics from a single-use cartridge model, supporting healthy product-level profitability. This margin structure provides room to absorb commercial expansion and fund R&D or regulatory work without immediate margin dilution, improving long-term resilience.
Large Installed Base & Recurring ConsumablesA broad installed base and disposable cartridge model create recurring, volume-driven revenue and predictable consumable demand. Global adoption across many hospitals supports steady procedure-led sales, enhances distributor leverage, and underpins scalable commercial economics over multiple years.
Strengthening Clinical Evidence & Regulatory PathRobust trial results and Breakthrough Device designations materially strengthen clinical credibility and payer conversations. Better clinical evidence raises physician adoption and reimbursement prospects, and a clearer regulatory path reduces long-term commercialization uncertainty if execution on additional data proceeds.
Bears Say
High LeverageSubstantial leverage and a compressed equity base limit financial flexibility and increase refinancing or covenant risk. High debt ratios constrain strategic choices, raise dilution likelihood if capital raises are needed, and make execution on clinical and commercial plans more contingent on external financing.
Persistent Cash BurnSustained negative operating and free cash flows indicate real cash consumption rather than accounting losses. With a modest cash balance reported (~$6.4M) and ongoing burn, the company faces a tangible funding need to sustain trials, regulatory submissions, and commercial expansion absent rapid cash‑flow breakeven or external financing.
Regulatory Delay & Added Data RequirementsThe FDA's request for extra mechanistic studies pushes the de novo timeline and raises incremental study costs. Delay into late 2026/early 2027 defers U.S. market access and TAM capture, increases resource needs, and prolongs reliance on international markets for growth and cash generation.
Cytosorbents News
CTSO FAQ
What was Cytosorbents Corp’s price range in the past 12 months?
Cytosorbents Corp lowest stock price was $0.43 and its highest was $1.39 in the past 12 months.
What is Cytosorbents Corp’s market cap?
Cytosorbents Corp’s market cap is $30.83M.
When is Cytosorbents Corp’s upcoming earnings report date?
Cytosorbents Corp’s upcoming earnings report date is Aug 04, 2026 which is in 65 days.
How were Cytosorbents Corp’s earnings last quarter?
Cytosorbents Corp released its earnings results on May 13, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.03.
Is Cytosorbents Corp overvalued?
According to Wall Street analysts Cytosorbents Corp’s price is currently Undervalued.
Does Cytosorbents Corp pay dividends?
Cytosorbents Corp does not currently pay dividends.
What is Cytosorbents Corp’s EPS estimate?
Cytosorbents Corp’s EPS estimate is -0.04.
How many shares outstanding does Cytosorbents Corp have?
Cytosorbents Corp has 62,794,746 shares outstanding.
What happened to Cytosorbents Corp’s price movement after its last earnings report?
Cytosorbents Corp reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -5.088%.
Which hedge fund is a major shareholder of Cytosorbents Corp?
Currently, no hedge funds are holding shares in CTSO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytosorbents Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.28%
12-Months-Change
Fundamentals
Return on Equity
-165.13%
Trailing 12-Months
Asset Growth
-20.12%
Trailing 12-Months
Company Description
Cytosorbents Corp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
CTSO Company Deck
CTSO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced operational and commercial progress against near‑term financial and regulatory challenges. Positives include modest top-line growth, strong international direct momentum (+13% YoY), healthy gross margins (69%), improved adjusted profitability metrics, strengthening clinical evidence (STAR-T showing >50% reduction in severe bleeding), and clearer regulatory direction with two FDA breakthrough designations. Main negatives are the widened GAAP net loss driven by FX, lower cash balance (~$6.4M), a delayed de novo submission requiring additional mechanistic studies and resources (likely pushing approval into late 2026/early 2027), Germany market softness, and a $0.5M order disruption tied to geopolitical events. Overall, management is executing cost reductions and targeting operating cash flow breakeven in H2 2026, and the call conveyed cautious optimism despite the identified risks.View all CTSO earnings summariesCTSO Stock 12 Month Forecast
Average Price Target
$0.75
▲(7.14% Upside)
Technical Analysis
Electrocore
―
TELA Bio
―
Spectral AI
―
Icecure Medical
―
Baird Medical Investment Holdings
―
Ownership Overview
5.93% Insiders
6.65% Mutual Funds
14.73% Other Institutional Investors
69.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---